RT Journal Article
SR Electronic
T1 Deciphering Risk of Recurrent Bone Stress Injury in Female Runners Using Serum Proteomics Analysis and Predictive Models
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.03.24318372
DO 10.1101/2024.12.03.24318372
A1 Romanowicz, Genevieve E.
A1 Popp, Kristin
A1 Dinh, Ethan
A1 Harker, Isabella R.
A1 Leguineche, Kelly
A1 Hughes, Julie M.
A1 Ackerman, Kathryn E.
A1 Bouxsein, Mary L.
A1 Guldberg, Robert E.
YR 2024
UL http://medrxiv.org/content/early/2024/12/05/2024.12.03.24318372.abstract
AB Up to 40% of elite athletes experience bone stress injuries (BSIs), with 20-30% facing reinjury. Early identification of runners at high risk of subsequent BSI could improve prevention strategies. However, the complex etiology and multifactorial risk factors of BSIs makes identifying predictive risk factors challenging. In a study of 30 female recreational athletes with tibial BSIs, 10 experienced additional BSIs over a 1-year period, prompting investigation of systemic biomarkers of subsequent BSIs using aptamer-based proteomic technology. We hypothesized that early proteomic signatures could discriminate runners who experienced subsequent BSIs. 1,500 proteins related to metabolic, immune, and bone healing pathways were examined. Using supervised machine learning and genetic programming methods, we analyzed serum protein signatures over the 1-year monitoring period. Models were also created with clinical metrics, including standard-of-care blood analysis, bone density measures, and health histories. Protein signatures collected within three weeks of BSI diagnosis achieved the greatest separation by sparse partial least squares discriminant analysis (sPLS-DA), clustering single and recurrent BSI individuals with a mean accuracy of 96 ± 0.02%. Genetic programming models independently verified the presence of candidate biomarkers, including fumarylacetoacetase, osteopontin, and trypsin-2, which significantly outperformed clinical metrics. Time-course differential expression analysis highlighted 112 differentially expressed proteins in individuals with additional BSIs. Gene set enrichment analysis mapped these proteins to pathways indicating increased fibrin clot formation and decreased immune signaling in recurrent BSI individuals. These findings provide new insights into biomarkers and dysregulated protein pathways associated with recurrent BSI and may lead to new preventative or therapeutic intervention strategies.One Sentence Summary Our study identified candidate serum biomarkers to predict subsequent bone stress injuries in female runners, offering new insights for clinical monitoring and interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUnited States Department of Defense, Defense Health Program, and Joint Program Committee (W811XWH-15-C-0024) (PI: Bouxsein ML); Wu Tsai Human Performance Alliance (Multi-PIs: Ackerman KE, Guldberg RE); NIH-NIDCR, K99DE033689 (PI: Romanowicz GE); Knight Campus Undergraduate Scholarship (Dinh) The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Army, the Department of Defense, National Institute of Health, or the U.S. Government. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the U.S. Army or the Department of Defense. Any citations of commercial organizations and trade names in this report do not constitute an official U.S. Army, Department of Defense endorsement of approval of the products or services of these organizations. This paper has been approved for public release with unlimited distribution. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board of Brigham and Women's Hosptial and Massachusets General Hospital gave ethical approval for this work (2015P000367/BWH). Informed consent was obtained from all participants prior to their enrollment. We confirm that all participant samples, data, and identifiers were securely managed by the research team and archived to safeguard participant confidentiality. All data presented are either aggregated or anonymized using scrambled participant identifiers.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors and will be published with the final peer-reviewed manuscript.